Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I' mode

TRAIL is a promising anticancer agent, capable of inducing apoptosis in a wide range of treatment-resistant tumor cells. In ‘type II' cells, the death signal triggered by TRAIL requires amplification via the mitochondrial apoptosis pathway. Consequently, deregulation of the intrinsic apoptosis-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillissen, B, Richter, A, Overkamp, T, Essmann, F, Hemmati, P G, Preissner, R, Belka, C, Daniel, P T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674381/
https://www.ncbi.nlm.nih.gov/pubmed/23703388
http://dx.doi.org/10.1038/cddis.2013.67

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674381/
https://www.ncbi.nlm.nih.gov/pubmed/23703388
http://dx.doi.org/10.1038/cddis.2013.67

Ejemplares similares